Evaluate performance metrics and benchmarks
RESEARCH presented at ACR Convergence 2025 highlights a potential new role for GLP-1 receptor agonists, medications widely used for type 2 diabetes and obesity, in the treatment of rheumatoid arthritis (RA)
These medications mimic the natural hormone glucagon-like peptide-1 (GLP-1) to influence glucose regulation and appetite-related signaling
However, replacing current GLP-1 drugs will depend on approval timing, safety, payer coverage, manufacturing capacity, and real-world persistence
Muscle fiber cross-sectional area increases at approximately 1.52% per week under optimal conditions (progressive overload, caloric surplus, 4080mcg IGF-1 LR3 daily)
The advanced facilities and technology we use